Maintenance therapy with the PARP inhibitor Lynparza olaparib added to Avastin bevacizumab resulted in a significant and clinically meaningful delay in cancer progression in patients with advanced stage III-IV ovarian cancer 160according to the results of [...]
Exposure to e-cigarette smoke caused mice to develop lung cancer a new study finds Published online October 7 inProceedings of National Academy of Sciences PNAS the study found that 9 of 40 mice 225 percent exposed to e-cigarette smoke with nicotine for 5 [...]
Initial treatment with Tagrisso osimertinib significantly lengthens overall survival compared to older generation EGFR-TKIs in patients with Ex19delL858R EGFR mutated advanced nonsmall cell lung cancer NSCLC according to results of the FLAURA clinical tri [...]
Progression-free survival PFS rates with erlotinib therapy plus bevacizumab forEGFR-positive nonsmall-cell lung cancer NSCLC were not superior to those seen with erlotinib monotherapy according to findings from a phase 2 clinical trial In the study Thomas [...]
A recent study supports what individuals with polycythemia vera PV have known for years PV associated symptoms are underappreciated by doctors and don8217t necessarily correlate with blood counts levels Individuals with PV can experience symptoms of fatig [...]
Dr Tanios Bekaii- Saab MD Program Head Mayo Clinic answered questions about management of advanced colo-rectal cancer CancerConnect and The Personalized Medicine Foundation were pleased to provide patients and caregivers the opportunity to ask questions a [...]
The United States Food and Drug Administration FDA granted accelerated approval to the combination of Keytruda pembrolizumab and Lenvima lenvatinib for the treatment of patients with advanced endometrial carcinoma that is not microsatellite instability hi [...]
Flumatinib may be more effective than Gleevec imatinib for initial treatment of chronic phase-chronic myeloid leukemia CML-CP according to study results presented at the 2019 American Society of Clinical Oncology ASCO Annual Meeting in Chicago Chronic mye [...]
The addition of isatuximab to pomalidomide and low-dose dexamethasone significantly improved PFS and overall response rate among patients with relapsed or refractory multiple myeloma according to randomized phase 3 study results presented at ASCO Annual M [...]
Results from the phase III PAOLA-1 clinical trial in women with advanced ovarian cancer evaluating maintenance therapy with Lynparza olaparib plus Avastin bevacizumab compared to Avastin alone in women with or without BRCA gene mutations have been release [...]
